BioSpace News Archive

Mersana Therapeutics, Inc. today announced the appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer, effective Monday, August 16, 2021.

Kiniksa Pharmaceuticals, Ltd. today announced the launch of a Named Patient Program for ARCALYST, a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling.

Praxis Precision Medicines, Inc. today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

SCYNEXIS, Inc. today reported financial results for the second quarter ended on June 30, 2021 and provided an update on recent clinical and corporate developments.

HiberCell announced today the acquisition of Genuity Science, Inc., a life science technology company that provides world-leading genomics and multi-omic analytics bolstered by an advanced artificial intelligence (AI) and machine learning (ML) platform to illuminate the underlying cause of cancer and other diseases.

Impel NeuroPharma today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

CM Life Sciences II today announced that the registration statement for their business combination has been declared effective by the US Securities Exchange Commission (“SEC” )

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the company’s Amplatzer™ Amulet™ Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), announced today that the Medicines and Healthcare products Regulatory Agency (MHRA), the pharmaceuticals regulator in the UK, agreed with Galmed’s plan to proceed with its proposed clinical studies with Aramchol meglumine in lieu of Aramchol free acid without the need to repeat nonclinical and clinical studies other than planned limited pharmacology studies relating to Aramchol meglumine.

NeuroBo Pharmaceuticals, Inc. today announced financial results for the second quarter ended June 30, 2021 .